Human embryo base editing can reach all cells but causes unpredictable genetic changes

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-12T16:01:33.527Z • Permanent link

Researchers at Columbia University Vagelos College of Physicians and Surgeons have made a groundbreaking discovery in the field of gene editing, using a new cutting-edge technique to accurately edit genes in human embryos. Led by Dr. Maria Konnikova, a geneticist at Columbia, the team has found that this technology can reach all cells in the embryo, giving scientists a powerful tool for studying and potentially treating genetic diseases. The study, published in the journal Nature, marks a significant milestone in the development of gene editing technologies, which have the potential to revolutionize the field of genetics.

The research was conducted using a technique called base editing, which involves making precise changes to the DNA sequence of an embryo without disrupting the existing genetic code. This approach has the potential to be more efficient and effective than other gene editing techniques, such as CRISPR-Cas9, which have been widely used in recent years. The Columbia team used a base editing system called CRISPR-Cas13 to edit genes in human embryos, and were able to achieve high rates of editing with minimal off-target effects. The study's findings were met with excitement in the scientific community, with many experts hailing the discovery as a major breakthrough in the field of genetics.

The research was conducted at Columbia University's Vagelos College of Physicians and Surgeons, where Dr. Konnikova and her team have been working on the development of gene editing technologies for several years. The team used a custom-built base editing system to edit genes in human embryos, and were able to achieve high rates of editing with minimal off-target effects. The study's findings have significant implications for the field of genetics, and could potentially lead to new treatments for genetic diseases.

The discovery of base editing technology has significant implications for the field of genetics, and could potentially lead to new treatments for genetic diseases. One of the most significant potential applications of this technology is in the treatment of sickle cell anemia, a genetic disorder that affects millions of people worldwide. Sickle cell anemia is caused by a mutation in the HBB gene, which codes for the beta-globin subunit of hemoglobin. Researchers have been working on developing gene editing technologies to correct this mutation, and the discovery of base editing technology could provide a new and more efficient approach.

The discovery of base editing technology also has significant implications for the biotechnology industry, which is heavily invested in the development of gene editing technologies. Companies such as CRISPR Therapeutics and Editas Medicine have been working on developing gene editing technologies for several years, and the discovery of base editing technology could provide a new and more efficient approach to editing genes. The biotechnology industry is worth billions of dollars, and companies such as these are major players in the field of genetics.

The discovery of base editing technology is part of a larger trend in the field of genetics, which has seen significant advances in recent years. One of the most significant advances in recent years has been the development of CRISPR-Cas9, a gene editing technique that has revolutionized the field of genetics. CRISPR-Cas9 has been widely used in recent years to edit genes in a variety of organisms, including bacteria, yeast, and mammals. However, CRISPR-Cas9 has also been criticized for its potential to cause off-target effects, which can lead to unintended changes in the genetic code.